Near future
Contacts
  • Home
  • Tech
  • Health
  • Environment
  • Architecture
  • energia
  • Transportation
  • Spazio
  • AI
  • concepts
  • Gadgets
  • Italy Next
  • H+
May 27, 2022

Coronavirus / Russia-Ukraine

Near future

News to understand, anticipate, improve the future.

No Result
View All Result

News to understand, anticipate, improve the future.

Read in:  Chinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

Coronavirus, dispute over Remdesivir. China: "useless". Fauci: “stop it, let's use it”.

The FDA's approval for emergency use of Remdesivir is expected for hours. Government consultant Anthony Fauci met journalists in the White House. But it is a clash over effectiveness.

Gianluca Ricciodi Gianluca Riccio
in Medicine
Share34Pin4Tweet12SendShare3ShareShare2
remdesivir fauci fda
April 29 2020
⚪ Reads in 4 minutes
A A

In spite of a first Chinese study that does not recommend its use (and the perplexities of the manufacturer itself), the study center directed by the consultant virologist of the White House presents enthusiastic results on the drug, and approves its emergency use.

Dr. Anthony S. Fauci called a study of an experimental drug against the coronavirus (born for other purposes), Remdesivir, "very optimistic". The FDA plans to announce the urgent use of antivirus treatment which would show reduced recovery times from the disease.

In these hours, therefore, the FDA announcement of an emergency use authorization of Remdesivir should arrive. Ahead of the announcement, President Trump and Dr. Anthony S. Fauci, the chief federal government scientist, met with reporters at the White House.

In the press conference, Dr. Fauci warned that the results of the study supervised by the NIAD, the National Institute of Allergy and Infectious Diseases, have yet to be adequately reviewed, but they expressed optimism that it could make a difference.

Maybe you are also interested

Far-UVC works in real scenarios: goodbye infections even indoors

Worldwide outbreak of acute childhood hepatitis: WHO investigates an Adenovirus

Almawave, wearable artificial intelligence that monitors COVID patients

Shanghai, now it's a nightmare: Omicron returns with interests (and a message)

In China, I have a different opinion

Among the first to experiment with the drug in the field (for obvious reasons) are the Chinese. I was talking about it here some time ago. Well, another study, conducted in China and published in the Lancet, has questioned the value of the drug for the treatment of seriously ill patients. Of course, it left open the possibility that it can be useful for others. However, the research on the latter is incomplete, due to the insufficiency of a congruous number of observers.

Fauci: "reduces recovery times by over a third"

Dr Fauci said Remdesivir could reduce recovery times by about a third. "Although a 31% improvement is not definitive, it is an important signal: because what it has shown is that a drug can block this virus," said Fauci. "This is very encouraging."

Trump echoes him, calling it a good sign. "It is certainly a positive event, it is a very positive event," said the US President.

The producers themselves hold back

In a statement, Gilead Sciences claimed to be "Aware of the positive data that emerged" from the study of the institute of Dr. Fauci. Very cautiously, then, the company adds: "We understand that the process has reached its primary endpoint and that NIAID will provide detailed information at an upcoming briefing." An acknowledgment that sounds rather lukewarm. And it is clear why: Remdesivir has not yet obtained a license or approval. Neither in the USA nor anywhere else in the world. "And it has not yet proven to be safe or effective for the treatment of Covid-19," they specify to Gilead herself.

The spokesperson, Ryan McKeel, said the company is unable to predict what actions the federal government will take. "However, we are continuing to discuss with them the growing body of evidence for remdesivir as a potential treatment for COVID-19, with the goal of making remdesivir more widely available to patients in urgent need of treatment." Meanwhile, after the announcement by Fauci, Gilead shares fly into the stock market.

Remdesivir has never been approved as a treatment for any disease. It was developed to combat Ebola, but the results of a clinical trial in Africa were also disappointing.

Expectations have been fueled by anecdotal reports of Covid-19 patients taking Remdesivir and reportedly recovering. Two of these reports were published in the prestigious New England Journal of Medicine, giving credibility to what the researchers later claimed as uncertain results.

Without comparative studies between the drug and a placebo, it was impossible to know whether the drug made a difference or whether patients improved on their own with normal supportive care.

Remdesivir's study published in Lancet found no benefit for the drug over placebo .

"Unfortunately, our study found that while safe and adequately tolerated, remdesivir did not provide significant benefits over placebo," said lead investigator of the new study, Dr. Bin Cao of China-Japan Friendship Hospital and Capital Beijing Medical University. “This is not the result we were hoping for,” he added.

The debate becomes increasingly heated, and confusion on the subject reigns supreme.

tags: Coronavirusredevive
Previous post

Dormio, MIT makes a device for lucid dreaming

Next Post

Coronavirus: in the long run, a better world.

COLLABORATE

To submit articles, disclose the results of a research or scientific discoveries write to the editorial staff
  • porters

    Winds of war, China launches the Zhu Hai Yun, the world's first "bearer"

    12218 Shares
    Share 4887 Tweet 3054
  • ETH technology: drinking water from the air 24 hours a day, without power supply

    10336 Shares
    Share 4133 Tweet 2583
  • Floating turbines: the strongest tidal flows in the world “tamed” to give energy

    2399 Shares
    Share 959 Tweet 600
  • Pearlsuites, Lazzarini brings out the hotel rooms on the water

    1970 Shares
    Share 788 Tweet 492
  • New study: electric batteries could last 100 years

    1537 Shares
    Share 614 Tweet 384

archive

Have a look here:

plants electrical signals
Environment

Plants "communicate" with electrical signals in the subsoil.

For the first time in the world, a study investigates the electrical signals transmitted by plants. A way of communicating ...

Read More
fine tobacco

New Zealand authorities still accelerate on the cessation of smoking and tobacco

Ascension, a vertical forest in Croatia

78165 1220468 alia250upsliverymountain2 623566

Beta Technologies and its incredible electric airplane

Robotics and neuroscience find meeting points

Next Post
coronavirus better world

Coronavirus: in the long run, a better world.

The daily tomorrow

Futuroprossimo.it provides news on the future of technology, science and innovation: if there is something that is about to arrive, here it has already arrived. FuturoProssimo is part of the network ForwardTo, studies and skills for future scenarios.

Subscribe to our newsletter

Environment
Architecture
Artificial intelligence
Gadgets
concepts
Design

Staff
Archives
Advertising
Privacy Policy

Medicine
Spazio
Robotica
Work
Transportation
energia

To contact the FuturoProssimo editorial team, write to redazione@futuroprossimo.it

Chinese Version
Édition Française
Deutsche Ausgabe
Japanese version
English Edition
Edição Portuguesa
Русское издание
Spanish edition

The daily tomorrow

Futuroprossimo.it provides news on the future of technology, science and innovation: if there is something that is about to arrive, here it has already arrived. FuturoProssimo is part of the network ForwardTo, studies and skills for future scenarios.

Chinese Version
Édition Française
Deutsche Ausgabe
Japanese version
English Edition
Edição Portuguesa
Русское издание
Spanish edition

Staff
Archives
Advertising
Privacy Policy

Subscribe to our newsletter

To contact the FuturoProssimo editorial team, write to redazione@futuroprossimo.it

Categories

This work is distributed under license Creative Commons Attribution 4.0 International.
© 2021 Futuroprossimo

No Result
View All Result
  • Home
  • Tech
  • Health
  • Environment
  • Architecture
  • energia
  • Transportation
  • Spazio
  • AI
  • concepts
  • Gadgets
  • Italy Next
  • H+
This site uses cookies. By continuing to read it, you consent to their use.